TrialBMC medicine2025

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Xiaolin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.